Neuron Bio joins the USA market

Neuron Bio (ticker: NEU), a leading company in biotechnology solutions created the company Neuron Bio USA INC in Boston, Massachusetts the last 28 October.

With the creation of a new corporation it is aimed to develop its strategic plan in the field of diagnostic for Alzheimer’s disease and to establish the contacts for the commercialization of the technologies developed in this area.

According to Javier S. Burgos, CEO of Neuron Bio, “Valorization of our developments in the field of diagnostic for Alzheimer’s involves joining the great American market. Due to this we have decided to constitute this new company in the USA with the main goal to strengthen this business line and to look for strategic partners that allow us to place in the market our developments in a minimum time possible. This was a step already outlined in our business plan. After recent positive contacts and negotiations we have opted for the area of Boston, the most appropriate for Neuron Bio due to its considerable concentration of biotech and pharma companies.”

The Boston area houses one of the world’s largest biotechnology cluster that currently has over 400 biotech companies, aside from the big pharmaceutical companies, specialized investors, patent lawyers, CROs (Contract Research Organization), etc.

Massachusetts is characterized by the presence of large research centers, centers of excellence and reference hospitals that are particularly interesting for the activity in the field of diagnostics for neurodegenerative diseases to be carried out by Neuron Bio Inc. Universities of Harvard and Boston, the MIT, the Massachusetts General Hospital and the Boston Medical Center are included among others.